Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014

Estudio descriptivo, de tipo observacional longitudinal en el que se evaluó la respuesta de uso de toxina en pacientes con cefalea crónica diaria, tratados en la clínica de toxina del Hospital Militar Central durante el periodo 2010 a 2014. La respuesta al uso de toxina se evaluó mediante escala vis...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2015
Institución:
Universidad Militar Nueva Granada
Repositorio:
Repositorio UMNG
Idioma:
spa
OAI Identifier:
oai:repository.unimilitar.edu.co:10654/7274
Acceso en línea:
http://hdl.handle.net/10654/7274
Palabra clave:
cefalea cronica diaria
toxina bolulinica
TOXINAS BOTULINICAS
TOXINAS BACTERIANAS
CEFALALGIA
MIGRAÑA
Chronic daily headache
Botulinum Toxin
Rights
License
http://purl.org/coar/access_right/c_abf2
id UNIMILTAR2_4992858c075a0a009921ed5ebe9ab926
oai_identifier_str oai:repository.unimilitar.edu.co:10654/7274
network_acronym_str UNIMILTAR2
network_name_str Repositorio UMNG
repository_id_str
dc.title.spa.fl_str_mv Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
dc.title.titleenglish.spa.fl_str_mv Response of botulinum toxin in patients with chronic headache tension a migraine type in the Military Hospital of Bogotá in the period of 2010 to 2014
title Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
spellingShingle Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
cefalea cronica diaria
toxina bolulinica
TOXINAS BOTULINICAS
TOXINAS BACTERIANAS
CEFALALGIA
MIGRAÑA
Chronic daily headache
Botulinum Toxin
title_short Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
title_full Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
title_fullStr Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
title_full_unstemmed Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
title_sort Respuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014
dc.contributor.advisor.none.fl_str_mv Meza Gaviria, Antonio
Guzman Molano, Luisa fernanda
dc.subject.spa.fl_str_mv cefalea cronica diaria
toxina bolulinica
topic cefalea cronica diaria
toxina bolulinica
TOXINAS BOTULINICAS
TOXINAS BACTERIANAS
CEFALALGIA
MIGRAÑA
Chronic daily headache
Botulinum Toxin
dc.subject.lemb.spa.fl_str_mv TOXINAS BOTULINICAS
TOXINAS BACTERIANAS
CEFALALGIA
MIGRAÑA
dc.subject.keyword.spa.fl_str_mv Chronic daily headache
Botulinum Toxin
description Estudio descriptivo, de tipo observacional longitudinal en el que se evaluó la respuesta de uso de toxina en pacientes con cefalea crónica diaria, tratados en la clínica de toxina del Hospital Militar Central durante el periodo 2010 a 2014. La respuesta al uso de toxina se evaluó mediante escala visual análoga del dolor (EVA), días de dolor y horas de dolor por día; antes y después de la aplicación de toxina. También se evaluó la ocurrencia de eventos adversos
publishDate 2015
dc.date.created.none.fl_str_mv 2015-08-13
dc.date.accessioned.none.fl_str_mv 2016-02-01T22:50:50Z
2019-12-30T19:04:46Z
dc.date.available.none.fl_str_mv 2016-02-01T22:50:50Z
2019-12-30T19:04:46Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.spa.spa.fl_str_mv Trabajo de grado
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10654/7274
url http://hdl.handle.net/10654/7274
dc.language.spa.fl_str_mv spa
language spa
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://purl.org/coar/access_right/c_abf2
dc.format.spa.fl_str_mv pdf
dc.coverage.spatial.spa.fl_str_mv Medicina
dc.publisher.spa.fl_str_mv Universidad Militar Nueva Granada
dc.publisher.department.spa.fl_str_mv Facultad de Medicina
dc.publisher.program.spa.fl_str_mv Neurología
institution Universidad Militar Nueva Granada
dc.source.bibliographicCitation.spa.fl_str_mv 1. Ahmed F, Parthasarathy R, Khalil. Chronic daily headaches. Ann Indian Acad Neurol. 2012 Aug;15:40-50.
3. Dodick DW, Mauskop A. Botulinum toxin type A for profilaxis chronic headache. Headache 2005, 45:315-324.
2. Midgette LA, Scher AI. The epidemiology of chronic daily headache. Curr Pain Headache Rep.2009;13: 59-63.
4. Dodick DW. Chronic daily headaches . New England Journal, 2006;354:158-65.
5. Shilpa P.S., Rashna K. Botulinum toxin: the mifdas touch. J Nat Sci Biol Med. 2014 Jan-Jun; 5(1): 8–14.
6. Ahmed F, Parthasarathy R, Khalil M. Chronic daily headaches. Ann Indian Acad Neurol .2012;15:40-50
7. Carod-Artal FJ, Irimia P, Ezpeleta D. chronic migraine: definition, epidemiology, risk factors and treatment. RevNeurol 2012; 54 (10): 629-637
8. Pradilla G, Muñoz Cerón F. Dolor de Cabeza: epidemiología e impacto. Acta Neurol Colomb 2013;29:3-10.
9. Sobrino F. Cefalea crónica diaria. Acta Neurol Colomb 2013;29:96-106
Ward T. Migraine Diagnosis and Pathophysiology, Continuum Lifelong Learning Neurol 2012;18:753–763
11. Volcy M. Pathophysiology of chronic migraine. Acta Neurol Colomb 2013;29:25-30.
12. Kaniecki RG. Tension type headache, Continuum Lifelong Learning Neurol 2012;823–834
13. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 suppl 1:9-160
14. Halker RB, Hastriter EV, Dodick DW. Chronic daily headache: an evidence-based and systematic approach to a challenging problem. Neurology. 2011;76(7 suppl 2): S37-S43
Yancey JR, Maj MC. Chronic Daily Headache: Diagnosis and Management. Am Fam Physician. 2014;89(8):642-648
16. Dodick DW. Clinical practice. Chronic daily headache [published correction appears in N Engl J Med. 2006;354(8):884]. N Engl J Med. 2006;354(2):158-165
17. Matharu MS, Goadsby PJ. Trigeminal autonomic cephalgias. J Neurol Neurosurg Psychiatry. 2002;72 suppl 2:ii19-ii26
18. Goadsby PJ, Boes C. Chronic daily headache. J Neurol Neurosurg Psychiatry. 2002;72 suppl 2:ii2-ii5
19. Jull G, Trott P, Potter H, et al. A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache. Spine (Phila Pa 1976). 2002;27(17): 1835-1843
20. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009;(1):CD001218
21. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for tension-type headache. Cochrane Database Syst Rev. 2009;(1):CD007587
22. Devineni T, Blanchard EB. A randomized controlled trial of an internet-based treatment for chronic headache. Behav Res Ther. 2005;43(3):277-292
23. Nash JM, Park ER, Walker BB, Gordon N, Nicholson RA. Cognitive-behavioral group treatment for disabling headache. Pain Med. 2004;5(2):178-186
24. Thorn BE, Pence LB, Ward LC, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8:938-949
25. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2014 Oct;34:944
26. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33-51
27. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005
28. Saper JR, Lake AE III, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470-482
29. Lake III AE. Chronic daily headache: new treatment strategies. Presented at the World Congress of Neurology (WCN), November 15–17, 2002
30. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily
31. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28:585-597
32. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Dabatase Syst Rev. 2004
33. Holroyd KA, O’Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy and their combination. JAMA 2001;285:2208–15
34. Drucker P, Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998; 38:687–90.
35. Dodick, D.W., Turkel, C.C., DeGryse, R.E., Aurora, S.K., Silberstein, S.D., Lipton, R.B., Diener, H.C., Brin, M.F., PREEMPT Chronic Migraine Study Group, 2010. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–936
36. Kerner, J., 1822. Das Fettgift oder die Fettsaure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Wursten giftig wirkenden Stoffes. Cotta, Stuttgart; Tu¨ bingen
37. Erbguth, F.J. From poison to remedy: the chequered history of botulinum toxin. J. Neural Transm. 2008; 115: 559–565
38. Barnes, M. Botulinum toxin-mechanisms of action and clinical use in spasticity. J. Rehabil. Med. 2008;115: 56–59.
39. Thenganatt, M.A., Fahn, S. Botulinum toxin for the treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 2012; 12: 399–409
40. Ivica M, Zdravko L. Botulinum toxin A, brain and pain. Progress in Neurobiology. 2014; 119–120
41. Grumelli C., Corradini I., Matteoli M., Verderio C. Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium, 2010; 47, 419–424
42. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012; 307:1736-1745
43. Straube A, Empl M, Ceballos-Baumann A, Tölle T, Stefenelli U, Pfaffenrath V. Pericranial injection of botulinum toxin type A (Dysport) fortension type headache - a multicentre,double-blind, randomized, placebo-controlled study. Eur J Neurol -2008; 15: 205-13
44. Erdemoglu AK. The long-term efficacy and safety of botulinum toxin in refractory chronic tension type headache. J Headache Pain .2007; 8: 294-300
45. Hamdy SM. Botulinum toxin: could it be an effective treatment for chronic tension type headache. J Headache Pain .2009; 10: 27-34
46. Harden RN. Botulinum toxin a in the treatment of chronic tension type headache with cervical myofascial trigger points: a
47. Karadaay O. Botulinum neuro-toxin type-A in the treatment of chronic tension type headache associated with pericranial tenderness]. - Agri - 01-JAN-2012; 24(1): 9-14
48. Blumenfeld AM1, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodiumfor proplylatic treatment of episodic or chronic migraine. Headache 2008; 48: 210-220
49. Mathew NT, Frahan JS.A double blind coparision of BOTOX and topiramato. Headache 2009; 49: 1466-1478
50. Jakubowski M et al. Exploding vs inplonding headache in migraine prophylaxis with botulinumtoxin A. Pain 2006; 105:286-295
bitstream.url.fl_str_mv http://repository.unimilitar.edu.co/bitstream/10654/7274/1/Documento%20final%20PROTOCOLO.pdf
http://repository.unimilitar.edu.co/bitstream/10654/7274/2/license.txt
http://repository.unimilitar.edu.co/bitstream/10654/7274/3/Documento%20final%20PROTOCOLO.pdf.txt
http://repository.unimilitar.edu.co/bitstream/10654/7274/4/Documento%20final%20PROTOCOLO.pdf.jpg
bitstream.checksum.fl_str_mv 3eb5dbdf29016f123d8f9cc64313d54c
57c1b5429c07cf705f9d5e4ce515a2f6
8ddb61719db483850a102fe2f4ddb503
76dc0c34fd8a44643951011cf1a20736
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional UMNG
repository.mail.fl_str_mv bibliodigital@unimilitar.edu.co
_version_ 1837098468413276160
spelling Meza Gaviria, AntonioGuzman Molano, Luisa fernandaUnda McFarlane, Maria CatalinaVargas Osorio, Julianacatalinaunda@gmail.comju_lianita@hotmail.comEspecialista en NeurologíaMedicina2016-02-01T22:50:50Z2019-12-30T19:04:46Z2016-02-01T22:50:50Z2019-12-30T19:04:46Z2015-08-13http://hdl.handle.net/10654/7274Estudio descriptivo, de tipo observacional longitudinal en el que se evaluó la respuesta de uso de toxina en pacientes con cefalea crónica diaria, tratados en la clínica de toxina del Hospital Militar Central durante el periodo 2010 a 2014. La respuesta al uso de toxina se evaluó mediante escala visual análoga del dolor (EVA), días de dolor y horas de dolor por día; antes y después de la aplicación de toxina. También se evaluó la ocurrencia de eventos adversosWe evaluated the response of botulinum toxin in patients with chronic headache, migraine and tension type in the Mikitary hospital. We observed a reduction in the duration time a severity.pdfspaUniversidad Militar Nueva GranadaFacultad de MedicinaNeurologíacefalea cronica diariatoxina bolulinicaTOXINAS BOTULINICASTOXINAS BACTERIANASCEFALALGIAMIGRAÑAChronic daily headacheBotulinum ToxinRespuesta del uso de toxina botulínica en paciente con cefalea crónica diaria: migraña y tipo tensión en el Hospital Militar Central en el periodo del 2010 al 2014Response of botulinum toxin in patients with chronic headache tension a migraine type in the Military Hospital of Bogotá in the period of 2010 to 2014info:eu-repo/semantics/bachelorThesisTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1f1. Ahmed F, Parthasarathy R, Khalil. Chronic daily headaches. Ann Indian Acad Neurol. 2012 Aug;15:40-50.3. Dodick DW, Mauskop A. Botulinum toxin type A for profilaxis chronic headache. Headache 2005, 45:315-324.2. Midgette LA, Scher AI. The epidemiology of chronic daily headache. Curr Pain Headache Rep.2009;13: 59-63.4. Dodick DW. Chronic daily headaches . New England Journal, 2006;354:158-65.5. Shilpa P.S., Rashna K. Botulinum toxin: the mifdas touch. J Nat Sci Biol Med. 2014 Jan-Jun; 5(1): 8–14.6. Ahmed F, Parthasarathy R, Khalil M. Chronic daily headaches. Ann Indian Acad Neurol .2012;15:40-507. Carod-Artal FJ, Irimia P, Ezpeleta D. chronic migraine: definition, epidemiology, risk factors and treatment. RevNeurol 2012; 54 (10): 629-6378. Pradilla G, Muñoz Cerón F. Dolor de Cabeza: epidemiología e impacto. Acta Neurol Colomb 2013;29:3-10.9. Sobrino F. Cefalea crónica diaria. Acta Neurol Colomb 2013;29:96-106Ward T. Migraine Diagnosis and Pathophysiology, Continuum Lifelong Learning Neurol 2012;18:753–76311. Volcy M. Pathophysiology of chronic migraine. Acta Neurol Colomb 2013;29:25-30.12. Kaniecki RG. Tension type headache, Continuum Lifelong Learning Neurol 2012;823–83413. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 suppl 1:9-16014. Halker RB, Hastriter EV, Dodick DW. Chronic daily headache: an evidence-based and systematic approach to a challenging problem. Neurology. 2011;76(7 suppl 2): S37-S43Yancey JR, Maj MC. Chronic Daily Headache: Diagnosis and Management. Am Fam Physician. 2014;89(8):642-64816. Dodick DW. Clinical practice. Chronic daily headache [published correction appears in N Engl J Med. 2006;354(8):884]. N Engl J Med. 2006;354(2):158-16517. Matharu MS, Goadsby PJ. Trigeminal autonomic cephalgias. J Neurol Neurosurg Psychiatry. 2002;72 suppl 2:ii19-ii2618. Goadsby PJ, Boes C. Chronic daily headache. J Neurol Neurosurg Psychiatry. 2002;72 suppl 2:ii2-ii519. Jull G, Trott P, Potter H, et al. A randomized controlled trial of exercise and manipulative therapy for cervicogenic headache. Spine (Phila Pa 1976). 2002;27(17): 1835-184320. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009;(1):CD00121821. Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for tension-type headache. Cochrane Database Syst Rev. 2009;(1):CD00758722. Devineni T, Blanchard EB. A randomized controlled trial of an internet-based treatment for chronic headache. Behav Res Ther. 2005;43(3):277-29223. Nash JM, Park ER, Walker BB, Gordon N, Nicholson RA. Cognitive-behavioral group treatment for disabling headache. Pain Med. 2004;5(2):178-18624. Thorn BE, Pence LB, Ward LC, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8:938-94925. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2014 Oct;34:94426. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33-5127. Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 200528. Saper JR, Lake AE III, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470-48229. Lake III AE. Chronic daily headache: new treatment strategies. Presented at the World Congress of Neurology (WCN), November 15–17, 200230. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily31. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28:585-59732. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Dabatase Syst Rev. 200433. Holroyd KA, O’Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy and their combination. JAMA 2001;285:2208–1534. Drucker P, Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998; 38:687–90.35. Dodick, D.W., Turkel, C.C., DeGryse, R.E., Aurora, S.K., Silberstein, S.D., Lipton, R.B., Diener, H.C., Brin, M.F., PREEMPT Chronic Migraine Study Group, 2010. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–93636. Kerner, J., 1822. Das Fettgift oder die Fettsaure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Wursten giftig wirkenden Stoffes. Cotta, Stuttgart; Tu¨ bingen37. Erbguth, F.J. From poison to remedy: the chequered history of botulinum toxin. J. Neural Transm. 2008; 115: 559–56538. Barnes, M. Botulinum toxin-mechanisms of action and clinical use in spasticity. J. Rehabil. Med. 2008;115: 56–59.39. Thenganatt, M.A., Fahn, S. Botulinum toxin for the treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 2012; 12: 399–40940. Ivica M, Zdravko L. Botulinum toxin A, brain and pain. Progress in Neurobiology. 2014; 119–12041. Grumelli C., Corradini I., Matteoli M., Verderio C. Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations. Cell Calcium, 2010; 47, 419–42442. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012; 307:1736-174543. Straube A, Empl M, Ceballos-Baumann A, Tölle T, Stefenelli U, Pfaffenrath V. Pericranial injection of botulinum toxin type A (Dysport) fortension type headache - a multicentre,double-blind, randomized, placebo-controlled study. Eur J Neurol -2008; 15: 205-1344. Erdemoglu AK. The long-term efficacy and safety of botulinum toxin in refractory chronic tension type headache. J Headache Pain .2007; 8: 294-30045. Hamdy SM. Botulinum toxin: could it be an effective treatment for chronic tension type headache. J Headache Pain .2009; 10: 27-3446. Harden RN. Botulinum toxin a in the treatment of chronic tension type headache with cervical myofascial trigger points: a47. Karadaay O. Botulinum neuro-toxin type-A in the treatment of chronic tension type headache associated with pericranial tenderness]. - Agri - 01-JAN-2012; 24(1): 9-1448. Blumenfeld AM1, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodiumfor proplylatic treatment of episodic or chronic migraine. Headache 2008; 48: 210-22049. Mathew NT, Frahan JS.A double blind coparision of BOTOX and topiramato. Headache 2009; 49: 1466-147850. Jakubowski M et al. Exploding vs inplonding headache in migraine prophylaxis with botulinumtoxin A. Pain 2006; 105:286-295http://purl.org/coar/access_right/c_abf2ORIGINALDocumento final PROTOCOLO.pdfapplication/pdf779589http://repository.unimilitar.edu.co/bitstream/10654/7274/1/Documento%20final%20PROTOCOLO.pdf3eb5dbdf29016f123d8f9cc64313d54cMD51LICENSElicense.txttext/plain1521http://repository.unimilitar.edu.co/bitstream/10654/7274/2/license.txt57c1b5429c07cf705f9d5e4ce515a2f6MD52TEXTDocumento final PROTOCOLO.pdf.txtExtracted texttext/plain88547http://repository.unimilitar.edu.co/bitstream/10654/7274/3/Documento%20final%20PROTOCOLO.pdf.txt8ddb61719db483850a102fe2f4ddb503MD53THUMBNAILDocumento final PROTOCOLO.pdf.jpgIM Thumbnailimage/jpeg7010http://repository.unimilitar.edu.co/bitstream/10654/7274/4/Documento%20final%20PROTOCOLO.pdf.jpg76dc0c34fd8a44643951011cf1a20736MD5410654/7274oai:repository.unimilitar.edu.co:10654/72742019-12-30 14:04:46.965Repositorio Institucional UMNGbibliodigital@unimilitar.edu.coRWwgYXV0b3IgZGUgbGEgb2JyYSAodGVzaXMsIG1vbm9ncmFmw61hIG8gdHJhYmFqbyBkZSBncmFkbyksIGFjdHVhbmRvIGVuIG5vbWJyZSBwcm9waW8sCkhhY2UgZW50cmVnYSBkZWwgZWplbXBsYXIgcmVzcGVjdGl2byB5IGRlIHN1cyBhbmV4b3MgZW4gZm9ybWF0byBkaWdpdGFsIG8gZWxlY3Ryw7NuaWNvLgoKWSBhdXRvcml6YSBhIGxhIFVOSVZFUlNJREFEIE1JTElUQVIgTlVFVkEgR1JBTkFEQSwgcGFyYSBxdWUgZW4gbG9zIHTDqXJtaW5vcyBlc3RhYmxlY2lkb3MgZW46CgotIExleSAyMyBkZSAxOTgyCi0gTGV5IDQ0IGRlIDE5OTMKLSBEZWNpc2nDs24gQW5kaW5hIDM1MSBkZSAxOTkzCi0gRGVjcmV0byA0NjAgZGUgMTk5NQoKeSBkZW3DoXMgbm9ybWFzIGdlbmVyYWxlcyBzb2JyZSBsYSBtYXRlcmlhLCB1dGlsaWNlIHkgdXNlIHBvciBjdWFscXVpZXIgbWVkaW8gY29ub2NpZG8gbyBwb3IgY29ub2NlciwKbG9zIGRlcmVjaG9zIHBhdHJpbW9uaWFsZXMgZGUgcmVwcm9kdWNjacOzbiwgY29tdW5pY2FjacOzbiBww7pibGljYSwgdHJhbnNmb3JtYWNpw7NuIHkgZGlzdHJpYnVjacOzbiBkZSBsYSBvYnJhIApvYmpldG8gZGVsIHByZXNlbnRlIGRvY3VtZW50by4KClBBUsOBR1JBRk86IExhIHByZXNlbnRlIGF1dG9yaXphY2nDs24gc2UgaGFjZSBleHRlbnNpdmEgbm8gc8OzbG8gYSBsYXMgZmFjdWx0YWRlcyB5IGRlcmVjaG9zIGRlIHVzbyBzb2JyZQpsYSBvYnJhIGVuIGZvcm1hdG8gbyBzb3BvcnRlIG1hdGVyaWFsLCBzaW5vIHRhbWJpw6luIHBhcmEgZm9ybWF0byB2aXJ0dWFsLCBlbGVjdHLDs25pY28sIGRpZ2l0YWwsIHkgY3V5byB1c28gc2UgZGUgZW4gcmVkLAppbnRlcm5ldCwgZXh0cmFuZXQsIGludHJhbmV0LCBldGMuLCB5IGVuIGdlbmVyYWwgZW4gY3VhbHF1aWVyIGZvcm1hdG8gY29ub2NpZG8gbyBwb3IgY29ub2Nlci4KCkVMIEVTVFVESUFOVEUgLSBBVVRPUiwgbWFuaWZpZXN0YSBxdWUgbGEgb2JyYSBvYmpldG8gZGUgbGEgcHJlc2VudGUgYXV0b3JpemFjacOzbiBlcyBvcmlnaW5hbCB5IGxhIHJlYWxpesOzIHNpbiB2aW9sYXIKbyB1c3VycGFyIGRlcmVjaG9zIGRlIGF1dG9yIGRlIHRlcmNlcm9zLCBwb3IgbG8gdGFudG8gbGEgb2JyYSBlcyBkZSBleGNsdXNpdmEgYXV0b3LDrWEgeSB0aWVuZSBsYSB0aXR1bGFyaWRhZCBzb2JyZSBsYSBtaXNtYS4KClBBUsOBR1JBRk86IEVuIGNhc28gZGUgcHJlc2VudGFyc2UgY3VhbHF1aWVyIHJlY2xhbWFjacOzbiBvIGFjY2nDs24gcG9yIHBhcnRlIGRlIHVuIHRlcmNlcm8gZW4gY3VhbnRvIGEgCmxvcyBkZXJlY2hvcyBkZSBhdXRvciBzb2JyZSBsYSBvYnJhIGVuIGN1ZXN0acOzbiwgRUwgRVNUVURJQU5URSAtIEFVVE9SLCBhc3VtaXLDoSB0b2RhIGxhIHJlc3BvbnNhYmlsaWRhZCwgCnkgc2FsZHLDoSBlbiBkZWZlbnNhIGRlIGxvcyBkZXJlY2hvcyBhcXXDrSBhdXRvcml6YWRvczsgcGFyYSB0b2RvcyBsb3MgZWZlY3RvcyBsYSB1bml2ZXJzaWRhZCBhY3TDumEgY29tbyAKdW4gdGVyY2VybyBkZSBidWVuYSBmZS4K

Publicaciones similares